The emerging role of dipeptidyl-peptidase-4 as a therapeutic target in lung disease

References

• WHO | disease burden and mortality estimates. Available from: https://www.who.int/healthinfo/global_burden_disease/estimates/en/
   Google Scholar
• Pearce N, Aït-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007;62:758–766.
   PubMed Web of Science ®Google Scholar
• Forum of International Respiratory Societies, European Respiratory Society. The global impact of respiratory disease – second Edition. 2017.
   Google Scholar
• Lambeir A-M, Durinx C, Scharpé S, et al. Dipeptidyl-peptidase iv from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209–294..
   PubMed Web of Science ®Google Scholar
• Nistala R, Savin V. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. Am J Physiol Renal Physiol. 2017;312:F661–F670.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Camerini D, Seed B, et al. Cloning and functional expression of the T cell activation antigen CD26. J Immunol. 1992;149:481–486.
   PubMed Web of Science ®Google Scholar
• O’Leary H, Ou X, Broxmeyer HE. The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. Curr Opin Hematol. 2013;20:314–319.
   PubMed Web of Science ®Google Scholar
• Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60:1917–1925.
   PubMed Web of Science ®Google Scholar
• Röhrborn D, Wronkowitz N. Eckel J. DPP4 in diabetes. Front Immunol. 2015;6:386..
   PubMed Web of Science ®Google Scholar
• Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci. 2005;108:277–292..
   PubMed Web of Science ®Google Scholar
• Schade J, Stephan M, Schmiedl A, et al. Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem. 2008;56:147–155.
   PubMed Web of Science ®Google Scholar
• Baseler L, de Wit E, Feldmann H. A comparative review of animal models of middle east respiratory syndrome coronavirus infection. Vet Pathol. 2016;53:521–531.
   PubMed Web of Science ®Google Scholar
• Gall MG, Chen Y, Vieira de Ribeiro AJ, et al. Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality. PLoS One. 2013;8:e78378.
   PubMed Web of Science ®Google Scholar
• Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010;59:1063–1073.
   PubMed Web of Science ®Google Scholar
• Conarello SL, Li Z, Ronan J, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. PNAS. 2003;100:6825–6830.
   PubMed Web of Science ®Google Scholar
• Wang XM, Holz LE, Chowdhury S, et al. The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury. Immunol Cell Biol. 2017;95:443–453.
   PubMed Web of Science ®Google Scholar
• Duarte N, Coelho I, Holovanchuk D, et al. Dipeptidyl peptidase-4 is a pro-recovery mediator during acute hepatotoxic damage and mirrors severe shifts in kupffer cells. Hepatol Commun. 2018;2:1080–1094.
   PubMed Web of Science ®Google Scholar
• Kameoka J, Tanaka T, Nojima Y, et al. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993;261:466.
   PubMed Web of Science ®Google Scholar
• Klemann C, Wagner L, Stephan M, et al. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185:1–21..
   PubMed Web of Science ®Google Scholar
• Yan S, Marguet D, Dobers J, et al. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol. 2003;33:1519–1527.
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008;29:295–301..
   PubMed Web of Science ®Google Scholar
• Hatano R, Ohnuma K, Yamamoto J, et al. CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production. Immunology. 2013;138:165–172.
   PubMed Web of Science ®Google Scholar
• Willheim M, Ebner C, Baier K, et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. J Allergy Clin Immunol. 1997;100:348–355.
   PubMed Web of Science ®Google Scholar
• Boonacker EP, Wierenga EA, Smits HH, et al. CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. J Histochem Cytochem. 2002;50:1169–1177.
   PubMed Web of Science ®Google Scholar
• El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis. 2012;55:218–228.
   PubMed Web of Science ®Google Scholar
• Anderluh M, Kocic G, Tomovic K, et al. DPP-4 inhibition: А novel therapeutic approach to the treatment of pulmonary hypertension? Pharmacol Ther. 2019;201:1–7..
   PubMed Web of Science ®Google Scholar
• Xu J, Wang J, He M, et al. Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension. Lab Invest. 2018;98:1333–1346.
   PubMed Web of Science ®Google Scholar
• Mentlein R. Dipeptidyl-peptidase IV (CD26)–role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9–24.
   PubMed Web of Science ®Google Scholar
• Nieto-Fontarigo JJ, González-Barcala FJ, San José E, et al. CD26 and Asthma: a Comprehensive Review. Clin Rev Allergy Immunol. 2019;56:139–160.
   PubMed Web of Science ®Google Scholar
• Portelli M, Sayers I. Genetic basis for personalized medicine in asthma. Expert Rev Respir Med. 2012;6:223–236.
   PubMed Web of Science ®Google Scholar
• Mathias RA, Grant AV, Rafaels N, et al. A genome-wide association study on African-ancestry populations for asthma. J Allergy Clin Immunol. 2010 Feb;125(2):336–346.e4.
   Google Scholar
• Chafekar A, Fielding BC. MERS-CoV: understanding the latest human coronavirus threat. Viruses. 2018;10:E93.
   PubMed Web of Science ®Google Scholar
• WHO | middle east respiratory syndrome coronavirus (MERS-CoV). WHO. Available from: http://www.who.int/emergencies/mers-cov/en/
   Google Scholar
• Zhou N, Zhang Y, Zhang J-C, et al. The receptor binding domain of MERS-CoV: the dawn of vaccine and treatment development. J Formos Med Assoc. 2014;113:143–147.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wong G, Lu G, et al. MERS-CoV spike protein: targets for vaccines and therapeutics. Antiviral Res. 2016;133:165–177.
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Haagmans BL, Hatano R, et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol. 2013;87:13892–13899.
   PubMed Web of Science ®Google Scholar
• Raj VS, Smits SL, Provacia LB, et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase. J Virol. 2014;88:1834–1838.
   PubMed Web of Science ®Google Scholar
• Vliegen G, Raju TK, Adriaensen D, et al. The expression of proline-specific enzymes in the human lung. Ann Transl Med. 2017;5:130.
   PubMed Web of Science ®Google Scholar
• Meyerholz DK, Lambertz AM, McCray PB. Dipeptidyl peptidase 4 distribution in the human respiratory tract. Am J Pathol. 2016;186:78–86.
   PubMed Web of Science ®Google Scholar
• Sand JMB, Knox AJ, Lange P, et al. Accelerated extracellular matrix turnover during exacerbations of COPD. Respir Res. 2015;16:69.
   PubMed Web of Science ®Google Scholar
• Metzemaekers M, Van Damme J, Mortier A, et al. Regulation of chemokine activity – a focus on the role of dipeptidyl peptidase IV/CD26. Front Immunol. 2016;7:483.
   PubMed Web of Science ®Google Scholar
• Havre PA, Abe M, Urasaki Y, et al. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008;13:1634–1645.
   PubMed Web of Science ®Google Scholar
• Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol. 2004;19:1345–1351.
   PubMed Web of Science ®Google Scholar
• Bishnoi R, Hong Y-R, Shah C, et al. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: a surveillance epidemiology and endpoint research medicare study. Cancer Med. 2019;8:3918–3927.
   PubMed Web of Science ®Google Scholar
• Ali A, Fuentes A, Skelton IWP, et al. A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers. Mol Clin Oncol. 2019;10:118–124.
   PubMed Web of Science ®Google Scholar
• Beckenkamp A, Willig JB, Santana DB, et al. Differential expression and enzymatic activity of DPPIV/CD26 affects migration ability of cervical carcinoma cells. PLoS One. 2015;10:e0134305.
   PubMed Web of Science ®Google Scholar
• Femia AP, Raimondi L, Maglieri G, et al. Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int J Cancer. 2013;133:2498–2503.
   PubMed Web of Science ®Google Scholar
• Garg MK, Kharb S, Pandit A. Prescribing gliptins: enthusiasm should be coupled with caution. Indian J Endocrinol Metab. 2012;16:324.
   PubMedGoogle Scholar
• Jang J-H, Baerts L, Waumans Y, et al. Suppression of lung metastases by the CD26/DPP4 inhibitor vildagliptin in mice. Clin Exp Metastasis. 2015;32:677–687.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang X, Wu R, et al. DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis. Oncotarget. 2017;8:8679–8692.
   PubMedGoogle Scholar
• Ohnuma K, Hatano R, Morimoto C. DPP4 in anti-tumor immunity: going beyond the enzyme. Nat Immunol. 2015;16:791–792.
   PubMed Web of Science ®Google Scholar
• Janssens R, Mortier A, Boff D, et al. Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes. Biochem Pharmacol. 2017;132:92–101.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43(Suppl):S42–51.
   PubMed Web of Science ®Google Scholar
• Liao Y, Ni Y, He R, et al. Clinical implications of fibroblast activation protein-α in non-small cell lung cancer after curative resection: a new predictor for prognosis. J Cancer Res Clin Oncol. 2013;139:1523–1528.
   PubMed Web of Science ®Google Scholar
• Ma Y, Wang J, Wang C, et al. DPP-4 inhibitor anagliptin protects against hypoxia-induced cytotoxicity in cardiac H9C2 cells. Artif Cells Nanomed Biotechnol. 2019;47:3823–3831.
   PubMed Web of Science ®Google Scholar
• Saito T, Ohnuma K, Suzuki H, et al. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors. Diabetes Res Clin Pract. 2013;102:e8–e12.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the. Circulation. 2014;130:1579–1588.
   PubMed Web of Science ®Google Scholar
• Stephan M, Suhling H, Schade J, et al. Effects of dipeptidyl peptidase-4 inhibition in an animal model of experimental asthma: a matter of dose, route, and time. Physiol Rep. 2013;1:e00095.
   PubMedGoogle Scholar
• Angevin E, Isambert N, Trillet-Lenoir V, et al. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. Br J Cancer. 2017;116:1126–1134.
   PubMed Web of Science ®Google Scholar